Table 2 Hemodialysis patient characteristics by frailty assessment score (n = 45)

Age, mean (s.d.)

60.4 (8.4)

70.5 (10.2)

71.7 (9.7)

p = 0.0776

69.9 (10.2)

Gender, Male

5 (100%)

20 (95.2%)

10 (100%)

p = 1.000

44 (97.8%)

Race/ethnicity, NH white

1 (20.0%)

9 (42.9%)

8 (42.1%)

p = 0.185

18 (40.0%)

 NH black

4 (80.0%)

7 (33.3%)

11 (57.9%)

22 (48.9%)

 NH Asian

0

1 (4.8%)

0

1 (2.2%)

 Hispanic

0

4 (10.0%)

0

4 (8.9%)

BMI, mean (s.d.)

33.3 (8.4)

29.9 (6.8)

27.1 (4.1)

p = 0.0901

29.1 (6.2)

Diabetes

3 (60.0%)

16 (76.2%)

15 (78.9%)

p = 0.700

34 (75.6%)

Hypertension

5 (100%)

19 (90.5%)

15 (79.0%)

p = 0.452

39 (86.7%)

Cerebrovascular accident (CVA)

0

3 (14.3%)

2 (10.5%)

p = 1.000

5 (11.1%)

Obstructive sleep apnea (OSA)

2 (40.0%)

9 (42.9%)

6 (31.6%)

p = 0.827

17 (37.8%)

Obesity

1 (20.0%)

9 (42.9%)

4 (21.0%)

p = 0.356

14 (31.1%)

Peripheral vascular disease (PVD)

0

3 (14.3%)

3 (15.8%)

p = 1.000

6 (13.3%)

Congestive heart failure or coronary artery disease

0

8 (38.1%)

11 (57.9%)

p = 0.071

19 (42.2%)

Vascular access, catheter

3 (60.0%)

1 (4.8%)

1 (5.3%)

p = 0.015

5 (11.1%)

 Arteriovenous graft

1 (20.0%)

3 (14.3%)

6 (31.6%)

10 (22.2%)

 Arteriovenous fistula

1 (20.0%)

17 (81.0%)

12 (63.2%)

30 (66.7%)

Access failure, yes

3 (60.0%)

9 (42.9%)

4(21.0%)

p = 0.180

16 (35.6%)

Dialysis vintage, mean (s.d.)

1.9 (1.5)

4.6 (3.6)

4.0 (3.0)

p = 0.2318

4.0 (3.2)

KT waitlist status, not a candidate

0

12 (57.1%)

11 (61.1%)

p = 0.144

23 (53.5%)

 Work up in progress

3 (75.0%)

8 (38.1%)

6 (33.3%)

17 (39.5%)

 Listed

1 (25.0%)

1 (4.8%)

1 (5.6%)

3 (7.0%)

Urea Reduction Ratio (> 67%), mean (s.d.)

70.5 (4.3)

75.2 (4.7)

73.6 (4.0)

p = 0.1030

74.0 (4.5)

KT/V ( > = 1.2), mean (s.d.)

1.3 (0.1)

1.5 (0.2)

1.4 (0.2)

p = 0.0783

1.5 (0.2)

Potassium (3.5–4.7 mmol/L), mean (s.d.)

4.2 (0.2)

4.2 (0.4)

4.4 (0.6)

p = 0.3754

4.3 (0.5)

Sodium (135–145 mmol/dL), mean (s.d.)

139.0 (1.2)

136.8 (3.0)

136.2 (2.6)

p = 0.1328

136.8 (2.8)

Phosphorous (3.5–5.5 mg/dL), mean (s.d.)

4.8 (1.1)

4.5 (0.7)

4.7 (1.2)

p = 0.8175

4.6 (1.0)

PTH (< 600 pg/dL), mean (s.d.)

668.8 (204.9)

577.2 (405.6)

701.8 (432.0)

p = 0.6154

640.0 (398.2)

Calcium (8.5–10.3 mg/dL), mean (s.d.)

8.7 (0.4)

8.7 (0.5)

9.0 (0.5)

p = 0.0624

8.8 (0.5)

Albumin (3.5–4.2 g/dL), mean (s.d.)

4.2 (0.3)

3.8 (0.4)

3.8 (0.7)

p = 0.3318

3.8 (0.6)

Hemoglobin (9–11 g/dl), mean (s.d.)

10.7 (0.7)

10.5 (1.0)

9.9 (1.4)

p = 0.2150

10.3 (1.2)

Charleston comorbidity index, median (IQR)

5 (5–5)

8 (6–9)

8 (6–8)

p = 0.1824

7 (5–8)

Estimated 10 years survival, 0%

1 (20.0%)

15 (71.4%)

14 (73.7%)

p = 0.099

30 (66.7%)

 2%

0

1 (4.8%)

1 (5.3%)

2 (4.4%)

 21%

3 (60.0%)

5 (23.8%)

3 (15.8%)

11 (24.4%)

 53%

1 (20.0%)

0

1 (5.3%)

2 (4.4%)

Pill count, mean (s.d.)

16.2 (6.0)

17.7 (10.9)

21.9 (6.4)

p = 0.2582

19.3 (8.9)

Life sustaining treatment, None

3 (60.0%)

7 (33.3%)

2 (10.5%)

p = 0.133

12 (26.7%)

 DNR and/or DNI

0

2 (9.5%)

5 (26.3%)

7 (15.6%)

 Full code

2 (40.0%)

12 (57.1%)

12 (63.2%)

26 (57.8%)

ACE or ARB, yes

0

1 (4.8%)

4 (21.0%)

p = 0.221

5 (11.1%)

CCB, yes

4 (80.0%)

6 (28.6%)

5 (26.3%)

p = 0.084

15 (33.3%)

Beta blockers, yes

3 (60.0%)

11 (52.4%)

8 (42.1%)

p = 0.697

22 (48.9%)

Diuretics, yes

1 (20.0%)

7 (33.3%)

5 (26.3%)

p = 0.899

13 (28.9%)

Alpha blockers, yes

0

4 (19.0%)

1 (5.3%)

p = 0.397

5 (11.1%)

Alpha-2 agonists, yes

0

1 (4.8%)

0

p = 1.000

1 (2.2%)

Vasodilators, yes

2 (40.0%)

3 (14.3%)

4 (21.0%)

p = 0.378

9 (20.0%)

Midodrine for hypotension during dialysis, yes

1 (20.0%)

3 (14.3%)

8 (42.1%)

p = 0.124

12 (26.7%)

ESA for anemia management, yes

2 (40.0%)

17 (81.0%)

16 (84.2%)

p = 0.138

35 (77.8%)

Phosphate binders, yes

4 (80.0%)

12 (57.1%)

12 (63.2%)

p = 0.634

28 (62.2%)